Short-term Air Pollution Exposure and In-hospital Outcomes in Patients With Acute Myocardial Infraction

Acute Myocardial Infarction Clinical Trial

Official title:

Short-term Air Pollution Exposure and In-hospital Outcomes in Patients With Acute Myocardial Infraction

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02652182
• Other study ID #: 20160006
• Status: Enrolling by invitation
• Phase: N/A
• First received: January 6, 2016
• Last updated: July 24, 2016
• Start date: January 2016

Study information

• Verified date: July 2016
• Source: Nanjing Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: the ethics committee of Huai'an First People's Hospital: China
• Study type: Observational

Clinical Trial Summary

The aim of this study is to investigate whether or not short-term expose to air pollution is associated with in-hospital outcomes, such as mortality and morbidity.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 600
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Less than 12 hours after the onset of myocardial infarction symptoms

• Documented acute ST (S- and T-wave)-segment elevation myocardial infarction

• Received emergent percutaneous coronary intervention

Exclusion Criteria:

• Age under 18-year old

Study Design

Observational Model: Case-Crossover, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Air Pollution
• Infarction
• Myocardial Infarction
• Percutaneous Coronary Intervention

Locations

Country	Name	City	State
China	Huai'an First People's Hospital, Nanjing Medical University	Huai'an	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
Nanjing Medical University	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major adverse cardiovascular events (MACE)		in the phase of hospital stay, up to 30 days	No
Secondary	Length of hospital stay		in the phase of hospital stay, up to 30 days	No
Secondary	ST (S- and T-wave) segment decreasing		within an hour after primary percutaneous coronary intervention	No
Secondary	left ventricular function	left ventricular ejection fraction in % and left ventricular end-diastolic diameter in mm, both are evaluated by echocardiography to assess the left ventricular function	in the phase of hospital stay, up to 30 days	No